军事知识服务平台
血清上皮细胞稳态-信号转导标志物对肝硬化患者发生临床显著性门静脉高压的预测价值
Predictive value of serum epithelial cell homeostasis-signal transduction markers for clinically significant portal hy-pertension in patients with liver cirrhosis
摘要 目的 探讨血清上皮细胞稳态-信号转导标志物细胞角蛋白 19 片段(CYFRA21-1)、β-抑制素 2(β-arrestin-2)对肝硬化患者发生临床显著性门静脉高压(CSPH)的预测价值.方法 选取 2021 年 4 月—2025 年 10 月国药同煤总医院消化内科收治的肝硬化患者 287 例作为肝硬化组,根据肝静脉压力梯度(HVPG)检测结果将肝硬化患者分为 CSPH 亚组 80 例和非 CSPH 亚组 207 例,另选取同期医院健康体检者 287 例作为健康对照组.采用酶联免疫吸附法检测血清 CYFRA21-1、β-arrestin-2水平;Pearson 分析血清 CYFRA21-1、β-arrestin-2 水平与 HVPG 值的相关性;多因素 Logistic 回归分析肝硬化患者发生 CSPH 的影响因素;受试者工作特征(ROC)曲线分析血清 CYFRA21-1、β-arrestin-2水平预测肝硬化患者发生 CSPH 的价值.结果 肝硬化组患者血清 CYFRA21-1、β-arrestin-2 水平高于健康对照组(t/P=23.097/<0.001、26.485/<0.001);CSPH 亚组血清 CYFRA21-1、β-arrestin-2 水平高于非 CSPH 亚组(t/P=13.927/<0.001、10.981/<0.001);血清 CYFRA21-1、β-arrestin-2 水平与 HVPG 呈正相关(r/P=0.615/<0.001、0.553/<0.001);CSPH 亚组食管胃底静脉曲张、Child-Pugh 分级 C 级比例及肝脏硬度值、FIB-4 指数、INR 高于非 CSPH 亚组,Alb、PLT 低于非 CSPH 亚组(χ2/t/P=22.182/<0.001、26.093/<0.001、22.177/<0.001、14.979/<0.001、12.222/<0.001、11.280/<0.001、18.463/<0.001);肝脏硬度值高、CYFRA21-1 高、β-arrestin-2 高是肝硬化患者发生 CSPH 的危险因素[OR(95%CI)=1.203(1.087~1.332)、1.844(1.286~2.645)、2.450(1.498~4.008)],PLT 高是保护因素[OR(95%CI)=0.972(0.955~0.990)];血清 CYFRA21-1、β-arrestin-2水平单独及二者联合诊断肝硬化患者发生 CSPH 的曲线下面积(AUC)分别为0.794、0.799、0.884,二者联合诊断的AUC 高于单独诊断(Z/P=3.738/<0.001、2.713/0.006).结论 肝硬化患者血清 CYFRA21-1、β-arrestin-2水平显著升高,且与 HVPG 及 CSPH 发生均密切相关,二者联合检测对肝硬化患者发生 CSPH 具有较高的预测价值.
Abstract:
Objective To investigate the predictive value of serum epithelial cell homeostasis-signal transduction markers—cytokeratin 19 fragment(CYFRA21-1)and β-arrestin-2—for the development of clinically significant portal hyper-tension(CSPH)in patients with liver cirrhosis.Methods A total of 287 patients with liver cirrhosis admitted to the Depart-ment of Gastroenterology,Sinopharm Tongmei General Hospital from April 2021 to October 2025 were enrolled as the cirrho-sis group,and 287 healthy individuals undergoing physical examinations at the same hospital during the same period were se-lected as the healthy control group.The cirrhosis group was further divided into a CSPH subgroup(80 cases)and a non-CSPH subgroup(207 cases)based on hepatic venous pressure gradient(HVPG)measurements.Serum levels of CYFRA21-1 and β-arrestin-2 were measured using enzyme-linked immunosorbent assay.Pearson correlation analysis was performed to assess the correlation between CYFRA21-1,β-arrestin-2,and HVPG values.Multivariate logistic regression analysis was used to identify risk factors for CSPH in patients with liver cirrhosis.Receiver operating characteristic(ROC)curves were applied to evaluate the value of CYFRA21-1 and β-arrestin-2 in predicting CSPH in cirrhotic patients.Results Serum levels of CYFRA21-1 and β-arrestin-2 in the cirrhosis group were significantly higher than those in the healthy control group(t=23.097,26.485;both P<0.001).Serum levels of CYFRA21-1 and β-arrestin-2 in the CSPH subgroup were significantly higher than those in the non-CSPH subgroup(t=13.927,10.981;both P<0.001).Serum CYFRA21-1 and β-arrestin-2 levels were positively correlated with HVPG values(r=0.615,0.553;both P<0.001).The proportions of esophagogastric varices,Child-Pugh grade C,liver stiffness measurement,FIB-4 index,and INR in the CSPH subgroup were significantly higher than those in the non-CSPH subgroup,while albumin and platelet counts were significantly lower(χ2/t=22.182,26.093,22.177,14.979,12.222,11.280,18.463;all P<0.001).High CYFRA21-1,high β-arrestin-2,and high liver stiffness measurement were inde-pendent risk factors for CSPH in patients with cirrhosis,while high platelet count was an independent protective factor[OR(95%CI)=1.844(1.286-2.645),2.450(1.498-4.008),1.203(1.087-1.332),0.972(0.955-0.990)].The AUCs of serum CYFRA21-1,β-arrestin-2,and their combination for diagnosing CSPH in patients with cirrhosis were 0.794,0.799,and 0.884,respectively.The combined diagnosis showed significantly higher AUC than either single marker(Z=3.738,2.713;P<0.001,0.006).Conclusion Serum levels of CYFRA21-1 and β-arrestin-2 are significantly elevated in patients with liver cirrhosis and are closely associated with HVPG and the development of CSPH.Combined detection of these two markers demonstrates high predictive value for CSPH in cirrhotic patients.